Cargando…

Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report

RATIONALE: Early onset epileptic encephalopathy (EOEE) is one of the most serious early onset epilepsies. The etiopathology of this condition remains unclear, and recent evidence indicated that gamma-aminobutyric acid (GABA) A receptor, subunit beta 3 (GABRB3) gene mutations might be associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yi, Lian, Yajun, Xie, Nanchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815790/
https://www.ncbi.nlm.nih.gov/pubmed/29390378
http://dx.doi.org/10.1097/MD.0000000000009273
_version_ 1783300570566623232
author Zhang, Yi
Lian, Yajun
Xie, Nanchang
author_facet Zhang, Yi
Lian, Yajun
Xie, Nanchang
author_sort Zhang, Yi
collection PubMed
description RATIONALE: Early onset epileptic encephalopathy (EOEE) is one of the most serious early onset epilepsies. The etiopathology of this condition remains unclear, and recent evidence indicated that gamma-aminobutyric acid (GABA) A receptor, subunit beta 3 (GABRB3) gene mutations might be associated with EOEE. Furthermore, the therapeutic regimen for EOEE has yet to be well elucidated. Herein, we reported the clinical and genetic features of a case with GABRB3-related EOEE. PATIENT CONCERNS: A 6-year-old girl developed epileptic seizures 3 days after birth. She presented with multiple seizure types including myoclonic seizures, spasms, and absence seizures. Serial electroencephalographic examinations showed variable abnormalities, and intellectual evaluation revealed significant development retardation. Conventional antiepileptic drugs were ineffective for the seizure controlling. Genetic screening identified a novel nonsense mutation (C.5G > A, p.W2X) in the GABRB3 gene. DIAGNOSES: Early onset epileptic encephalopathy. INTERVENTIONS: We changed the antiepileptic strategy to oral clonazepam (0.5mg twice daily). The patient was followed up once a week and significant declining in the attack frequency was noted 1 week later (2–3 times daily). Subsequently, the dosage was doubled (1mg twice daily), and complete cessation of seizures was achieved 20 days later. OUTCOMES: Through a 9-month follow up,the girl remained seizure-free. LESSONS: This study identified a novel nonsensemutation (C.5G>A) in the exon 1 of GABRB3 Gene, which may be associated with EOEE. To our knowledge, this is the first report to use clonazepam in the patient with GABRB3-related EOEE with favorable outcome. Our finding suggested that clonazepam might be a choice for patient with GABRB3-related EOEE. The remarkable efficacy of clonazepam in the control of seizures indicated a potential GABRB3- or GABA-related mechanism involved in the development of EOEE.
format Online
Article
Text
id pubmed-5815790
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-58157902018-02-28 Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report Zhang, Yi Lian, Yajun Xie, Nanchang Medicine (Baltimore) 5300 RATIONALE: Early onset epileptic encephalopathy (EOEE) is one of the most serious early onset epilepsies. The etiopathology of this condition remains unclear, and recent evidence indicated that gamma-aminobutyric acid (GABA) A receptor, subunit beta 3 (GABRB3) gene mutations might be associated with EOEE. Furthermore, the therapeutic regimen for EOEE has yet to be well elucidated. Herein, we reported the clinical and genetic features of a case with GABRB3-related EOEE. PATIENT CONCERNS: A 6-year-old girl developed epileptic seizures 3 days after birth. She presented with multiple seizure types including myoclonic seizures, spasms, and absence seizures. Serial electroencephalographic examinations showed variable abnormalities, and intellectual evaluation revealed significant development retardation. Conventional antiepileptic drugs were ineffective for the seizure controlling. Genetic screening identified a novel nonsense mutation (C.5G > A, p.W2X) in the GABRB3 gene. DIAGNOSES: Early onset epileptic encephalopathy. INTERVENTIONS: We changed the antiepileptic strategy to oral clonazepam (0.5mg twice daily). The patient was followed up once a week and significant declining in the attack frequency was noted 1 week later (2–3 times daily). Subsequently, the dosage was doubled (1mg twice daily), and complete cessation of seizures was achieved 20 days later. OUTCOMES: Through a 9-month follow up,the girl remained seizure-free. LESSONS: This study identified a novel nonsensemutation (C.5G>A) in the exon 1 of GABRB3 Gene, which may be associated with EOEE. To our knowledge, this is the first report to use clonazepam in the patient with GABRB3-related EOEE with favorable outcome. Our finding suggested that clonazepam might be a choice for patient with GABRB3-related EOEE. The remarkable efficacy of clonazepam in the control of seizures indicated a potential GABRB3- or GABA-related mechanism involved in the development of EOEE. Wolters Kluwer Health 2017-12-15 /pmc/articles/PMC5815790/ /pubmed/29390378 http://dx.doi.org/10.1097/MD.0000000000009273 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 5300
Zhang, Yi
Lian, Yajun
Xie, Nanchang
Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report
title Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report
title_full Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report
title_fullStr Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report
title_full_unstemmed Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report
title_short Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report
title_sort early onset epileptic encephalopathy with a novel gabrb3 mutation treated effectively with clonazepam: a case report
topic 5300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815790/
https://www.ncbi.nlm.nih.gov/pubmed/29390378
http://dx.doi.org/10.1097/MD.0000000000009273
work_keys_str_mv AT zhangyi earlyonsetepilepticencephalopathywithanovelgabrb3mutationtreatedeffectivelywithclonazepamacasereport
AT lianyajun earlyonsetepilepticencephalopathywithanovelgabrb3mutationtreatedeffectivelywithclonazepamacasereport
AT xienanchang earlyonsetepilepticencephalopathywithanovelgabrb3mutationtreatedeffectivelywithclonazepamacasereport